Search

Objective: This study aimed at evaluating whether subcutaneous and pre-peritoneal abdominal fat as well as follicular fluid leptin (FFL) predict intracytoplasmic sperm injection (ICSI) outcomes in women without polycystic ovary syndrome (PCOS) Design: Prospective cohort study (NCT03778684) in an University-affiliated Assisted Conception Center University IRB approved the study Materials and Methods: Infertile non-PCOS women indicated for ICSI were considered for enrollment after consent Included women were grouped based on their waist circumference (WC) into women with central obesity (WC ≥ 80 cm;COB group) and without (WC< 80 cm;Non-COB group) At baseline evaluation, women underwent assessment of obesity using different measures and assessment of homeostasis-model for insulin resistance (HOMA-IR) Obesity measures included body mass index (BMI), visceral adiposity index (VAI), and the novel body fat index (BFI) BFI was calculated by multiplying pre-peritoneal and subcutaneous fat (in mm) and divided by height (in cm) FFL was measured from pooled follicular fluid of ≥ 17 mm follicles, containing cumulus oocyte complex Our primary endpoint was ongoing pregnancy rate (OPR) Comparisons between groups were evaluated utilizing the independent t, Wilcoxon rank sum, and chi-square tests as appropriate Logistic regression model, receiver operating characteristic (ROC) curve and correlation coefficient (r) were also utilized We planned a sample size of 168 women Recruitment was temporarily suspended due to COVID-19 pandemic Recruitment will continue, once IVF procedures are resumed based on our governmental policy Results: Of 340 women screened, 72 eligible women were included in this preliminary analysis;40 in COB group and 32 in Non-COB group Both groups were comparable in age, AMH, duration of infertility, IVF indication, HOMA-IR, cycle characteristics and FFL concentrations Women in COB group were more likely to have higher BMI (mean±SD;30 5±3 9vs25 3±2 8 p < 0 005), BFI (median(IQR),1 8(1 8) vs0 73(0 2), p

Introduction: This study compares the efficacy of a levonorgestrel-releasing intrauterine system (LNG-IUS) and a low-dose combined oral contraceptive (COC) in reducing adenomyosis-related pain and bleeding. Materials and methods: A randomized clinical trial included 62 participants complaining of pain and bleeding that was associated with adenomyosis. Participants were randomly assigned to either LNG-IUS or COC treatment. The outcomes included the improvement of pain using a visual analogue scale, menstrual blood loss using a menstrual diary and estimated uterine volume by ultrasound for 6 months of treatment. We also compared uterine arteries and intramyometrial Doppler indices before and 6 months after treatment with both LNG-IUS and COCs. Results: Both treatments significantly reduced pain after 6 months of use; however, the reduction was greater in the LNG-IUS group (from 6.23±0.67 to 1.68±1.25) compared with the COCs group (from 6.55±0.68 to 3.90±0.54). Both treatment arms significantly decreased the number of bleeding days, uterine volume and Doppler blood flow in the uterus from before to after treatment. These effects were more significant in the LNG-IUS arm compared with the COC arm. Conclusion: Both LNG-IUS and COCs decreased the pain and menstrual bleeding that is associated with adenomyosis. However, LNG-IUS is more effective than the COCs in reducing pain and menstrual blood loss. This effect may be secondary to the decrease in uterine volume and the increase in blood flow resistance. © 2015 Elsevier Inc. All rights reserved.